We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6645:TSEOMRON Corporation Analysis

Data as of 2026-06-07 - not real-time

NT$12.95

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Kim Forest Enterprise is trading at TWD 12.95, just above the calculated support of TWD 11.40 and touching the resistance of TWD 12.95, while the 20‑day SMA (12.12) and 50‑day SMA (12.80) sit below the current price, indicating a short‑term price lift but a longer‑term bearish backdrop. Technical signals are mixed: the RSI at 61.8 suggests momentum is still healthy, the MACD line (‑0.236) is above its signal (‑0.351) and the histogram is positive, hinting at a brief bullish impulse despite the overall trend being labeled “bearish.” Volume is increasing, which can fuel the near‑term rally, yet the 30‑day volatility of 34.5% and a historical max drawdown of 55.5% underscore a volatile price environment. Fundamentally, the company is struggling – operating margin is –14.7%, profit margin –26.7%, and EPS is negative (‑2.41), with operating cash flow and free cash flow both in the red. The balance sheet shows a debt‑to‑equity ratio of 74.8% and total debt (TWD 383.9 M) far exceeding cash on hand (TWD 123.7 M), raising solvency concerns. The price‑to‑book of 1.6 and price‑to‑sales of 1.42 appear modest, yet without earnings the valuation leans toward being overvalued. Market sentiment is extremely greedy (Fear‑Greed Index 83), which may be inflating the price temporarily, but the underlying financial weakness suggests a likely correction.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • MACD histogram turning positive but limited by bearish SMA alignment
  • Price at resistance level with limited upside
  • High short‑term volatility

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Negative earnings and operating margins
  • High debt‑to‑equity ratio and cash‑flow deficits
  • Price below 20‑day and 50‑day moving averages

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Potential growth in genetic‑testing and diagnostics market
  • Significant regulatory and approval risk
  • Need for a turnaround in cash‑flow generation

Key Metrics & Analysis

Financial Health

Revenue Growth11.00%
Profit Margin-26.67%
ROE-25.77%
ROA-8.26%
Debt/Equity74.84
P/B Ratio1.6
Op. Cash FlowNT$-57167000
Free Cash FlowNT$-8231125
Industry P/E27.9

Technical Analysis

TrendBearish
RSI61.8
SupportNT$11.40
ResistanceNT$12.95
MA 20NT$12.12
MA 50NT$12.80
MA 200NT$17.81
MACDBullish
VolumeIncreasing
Fear & Greed Index83.02

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta-0.05
Volatility34.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.